Total Payments
$1.2M
2024 Payments
$158,228
Companies
49
Transactions
1,422
Medicare Patients
848
Medicare Billing
$209,765
Payment Breakdown by Category
Other$688,876 (55.3%)
Consulting$318,014 (25.5%)
Travel$158,675 (12.7%)
Research$45,176 (3.6%)
Food & Beverage$33,480 (2.7%)
Education$1,822 (0.1%)
Gifts$54.25 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $583,505 | 190 | 46.8% |
| Consulting Fee | $318,014 | 94 | 25.5% |
| Travel and Lodging | $158,675 | 445 | 12.7% |
| Honoraria | $56,758 | 15 | 4.6% |
| Unspecified | $45,176 | 27 | 3.6% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $41,975 | 13 | 3.4% |
| Food and Beverage | $33,480 | 520 | 2.7% |
| Grant | $6,200 | 1 | 0.5% |
| Education | $1,822 | 51 | 0.1% |
| Compensation for serving as faculty or as a speaker for a medical education program | $437.82 | 1 | 0.0% |
| Gift | $54.25 | 65 | 0.0% |
Payments by Type
General
$1.2M
1,395 transactions
Research
$45,176
27 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| MAYNE PHARMA COMMERCIAL LLC | $214,068 | 156 | $0 (2024) |
| AMAG Pharmaceuticals, Inc. | $196,129 | 282 | $0 (2022) |
| AbbVie Inc. | $179,507 | 219 | $0 (2023) |
| TherapeuticsMD, Inc. | $80,941 | 110 | $0 (2022) |
| Duchesnay USA Incorporated | $73,082 | 101 | $0 (2023) |
| Bayer Healthcare Pharmaceuticals Inc. | $71,662 | 57 | $0 (2024) |
| Shionogi Inc | $62,428 | 35 | $0 (2017) |
| ASCEND THERAPEUTICS US, LLC | $52,741 | 88 | $0 (2024) |
| Astellas Pharma US Inc | $38,092 | 32 | $0 (2024) |
| Allergan Inc. | $35,474 | 52 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $158,228 | 125 | MAYNE PHARMA COMMERCIAL LLC ($103,642) |
| 2023 | $197,447 | 176 | MAYNE PHARMA COMMERCIAL LLC ($110,426) |
| 2022 | $99,626 | 76 | Myovant Sciences GmbH ($32,597) |
| 2021 | $49,463 | 44 | Bayer HealthCare Pharmaceuticals Inc. ($27,112) |
| 2020 | $25,182 | 25 | Sebela Pharmaceuticals Inc. ($9,000) |
| 2019 | $200,566 | 280 | AbbVie, Inc. ($91,759) |
| 2018 | $289,924 | 404 | AMAG Pharmaceuticals, Inc. ($118,918) |
| 2017 | $225,661 | 292 | Shionogi Inc ($62,428) |
All Payment Transactions
1,422 individual payment records from CMS Open Payments — Page 1 of 57
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/16/2024 | MAYNE PHARMA COMMERCIAL LLC | NEXTSTELLIS (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,600.00 | General |
| Category: CONTRACEPTIVE | ||||||
| 12/16/2024 | MAYNE PHARMA COMMERCIAL LLC | NEXTSTELLIS (Drug) | Travel and Lodging | In-kind items and services | $1,059.64 | General |
| Category: CONTRACEPTIVE | ||||||
| 12/16/2024 | MAYNE PHARMA COMMERCIAL LLC | NEXTSTELLIS (Drug) | Food and Beverage | In-kind items and services | $108.54 | General |
| Category: CONTRACEPTIVE | ||||||
| 12/03/2024 | Sumitomo Pharma America, Inc. | MYFEMBREE (Drug) | Food and Beverage | In-kind items and services | $24.49 | General |
| Category: HORMONE THERAPY | ||||||
| 12/02/2024 | BESINS HEALTHCARE IRELAND LIMITED | — | Honoraria | Cash or cash equivalent | $16,000.00 | General |
| 11/20/2024 | MAYNE PHARMA COMMERCIAL LLC | ANNOVERA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $6,000.00 | General |
| Category: CONTRACEPTIVE | ||||||
| 11/20/2024 | MAYNE PHARMA COMMERCIAL LLC | ANNOVERA (Drug) | Travel and Lodging | In-kind items and services | $244.72 | General |
| Category: CONTRACEPTIVE | ||||||
| 11/20/2024 | MAYNE PHARMA COMMERCIAL LLC | ANNOVERA (Drug) | Travel and Lodging | In-kind items and services | $192.66 | General |
| Category: CONTRACEPTIVE | ||||||
| 11/20/2024 | MAYNE PHARMA COMMERCIAL LLC | ANNOVERA (Drug) | Food and Beverage | In-kind items and services | $124.66 | General |
| Category: CONTRACEPTIVE | ||||||
| 11/19/2024 | MAYNE PHARMA COMMERCIAL LLC | NEXTSTELLIS (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $6,000.00 | General |
| Category: CONTRACEPTIVE | ||||||
| 11/19/2024 | MAYNE PHARMA COMMERCIAL LLC | NEXTSTELLIS (Drug) | Travel and Lodging | In-kind items and services | $910.34 | General |
| Category: CONTRACEPTIVE | ||||||
| 11/19/2024 | MAYNE PHARMA COMMERCIAL LLC | NEXTSTELLIS (Drug) | Food and Beverage | Cash or cash equivalent | $543.93 | General |
| Category: CONTRACEPTIVE | ||||||
| 11/19/2024 | MAYNE PHARMA COMMERCIAL LLC | NEXTSTELLIS (Drug) | Travel and Lodging | In-kind items and services | $244.71 | General |
| Category: CONTRACEPTIVE | ||||||
| 11/19/2024 | MAYNE PHARMA COMMERCIAL LLC | NEXTSTELLIS (Drug) | Food and Beverage | In-kind items and services | $124.74 | General |
| Category: CONTRACEPTIVE | ||||||
| 11/12/2024 | MAYNE PHARMA COMMERCIAL LLC | NEXTSTELLIS (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $6,000.00 | General |
| Category: CONTRACEPTIVE | ||||||
| 11/12/2024 | MAYNE PHARMA COMMERCIAL LLC | NEXTSTELLIS (Drug) | Travel and Lodging | In-kind items and services | $542.95 | General |
| Category: CONTRACEPTIVE | ||||||
| 11/12/2024 | MAYNE PHARMA COMMERCIAL LLC | NEXTSTELLIS (Drug) | Food and Beverage | Cash or cash equivalent | $190.91 | General |
| Category: CONTRACEPTIVE | ||||||
| 11/12/2024 | MAYNE PHARMA COMMERCIAL LLC | NEXTSTELLIS (Drug) | Travel and Lodging | In-kind items and services | $153.60 | General |
| Category: CONTRACEPTIVE | ||||||
| 11/12/2024 | MAYNE PHARMA COMMERCIAL LLC | NEXTSTELLIS (Drug) | Food and Beverage | In-kind items and services | $108.11 | General |
| Category: CONTRACEPTIVE | ||||||
| 11/04/2024 | Lilly USA, LLC | MOUNJARO (Drug), ZEPBOUND | Food and Beverage | In-kind items and services | $81.58 | General |
| Category: Diabetes | ||||||
| 11/03/2024 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $18.59 | General |
| Category: Obesity | ||||||
| 10/19/2024 | BESINS HEALTHCARE IRELAND LIMITED | — | Travel and Lodging | Cash or cash equivalent | $6,480.69 | General |
| 10/16/2024 | Radius Health, Inc. | — | Food and Beverage | In-kind items and services | $38.18 | General |
| 10/10/2024 | MAYNE PHARMA COMMERCIAL LLC | NEXTSTELLIS (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,800.00 | General |
| Category: CONTRACEPTIVE | ||||||
| 10/10/2024 | MAYNE PHARMA COMMERCIAL LLC | NEXTSTELLIS (Drug) | Travel and Lodging | In-kind items and services | $1,250.59 | General |
| Category: CONTRACEPTIVE | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Phase 3, Single-Arm, Open-Label Study to Evaluate the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are 18 to 50 Years of Age and at Risk for Pregnancy | Myovant Sciences GmbH | $28,304 | 8 |
| Mona Lisa Touch | Cytyc Corporation | $8,145 | 2 |
| Study of the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis | Myovant Sciences GmbH | $4,293 | 3 |
| A Phase 3 Study to Evaluate the Safety and Efficacy of Elagolix in Combination With Estradiol/Norethindrone Acetate in Subjects With Moderate to Severe Endometriosis-Associated Pain | AbbVie Inc. | $4,057 | 13 |
| BAY1002670 Long term Safety vs SoC | Bayer HealthCare Pharmaceuticals Inc. | $378.17 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2022 | 4 | 130 | 1,152 | $56,345 | $26,806 |
| 2021 | 7 | 395 | 3,733 | $194,659 | $99,952 |
| 2020 | 6 | 323 | 3,318 | $164,558 | $83,007 |
Total Patients
848
Total Services
8,203
Medicare Billing
$209,765
Procedure Codes
17
All Medicare Procedures & Services
17 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0897 | Injection, denosumab, 1 mg | Office | 2022 | 16 | 1,020 | $22,440 | $16,615 | 74.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 88 | 103 | $28,325 | $8,255 | 29.1% |
| 76830 | Ultrasound scan of uterus, ovaries, tubes, cervix and pelvic area through vagina | Office | 2022 | 14 | 16 | $4,800 | $1,855 | 38.6% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2022 | 12 | 13 | $780.00 | $81.18 | 10.4% |
| J0897 | Injection, denosumab, 1 mg | Office | 2021 | 31 | 3,180 | $69,960 | $52,248 | 74.7% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 224 | 376 | $94,634 | $38,140 | 40.3% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 29 | 29 | $13,950 | $4,022 | 28.8% |
| 76830 | Ultrasound pelvis through vagina | Office | 2021 | 21 | 28 | $8,400 | $3,259 | 38.8% |
| G0101 | Cervical or vaginal cancer screening; pelvic and clinical breast examination | Office | 2021 | 31 | 31 | $3,100 | $1,439 | 46.4% |
| 96372 | Injection beneath the skin or into muscle for therapy, diagnosis, or prevention | Office | 2021 | 30 | 60 | $3,600 | $715.79 | 19.9% |
| 82270 | Stool analysis for blood to screen for colon tumors | Office | 2021 | 29 | 29 | $1,015 | $127.02 | 12.5% |
| J0897 | Injection, denosumab, 1 mg | Office | 2020 | 28 | 2,880 | $63,360 | $44,983 | 71.0% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 200 | 313 | $75,998 | $29,071 | 38.3% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Office | 2020 | 39 | 39 | $14,440 | $5,398 | 37.4% |
| 76830 | Ultrasound pelvis through vagina | Office | 2020 | 21 | 25 | $7,440 | $2,901 | 39.0% |
| 96372 | Injection beneath the skin or into muscle for therapy, diagnosis, or prevention | Office | 2020 | 23 | 49 | $2,900 | $602.47 | 20.8% |
| 82270 | Stool analysis for blood to screen for colon tumors | Office | 2020 | 12 | 12 | $420.00 | $52.29 | 12.5% |
About Dr. James Simon, M.D
Dr. James Simon, M.D is a Reproductive Endocrinology healthcare provider based in Washington, District of Columbia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 12/12/2006. The National Provider Identifier (NPI) number assigned to this provider is 1700947256.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. James Simon, M.D has received a total of $1.2M in payments from pharmaceutical and medical device companies, with $158,228 received in 2024. These payments were reported across 1,422 transactions from 49 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($583,505).
As a Medicare-enrolled provider, Simon has provided services to 848 Medicare beneficiaries, totaling 8,203 services with total Medicare billing of $209,765. Data is available for 3 years (2020–2022), covering 17 distinct procedure/service records.
Ad
Practice Information
- Specialty Reproductive Endocrinology
- Other Specialties Gynecology
- Location Washington, DC
- Active Since 12/12/2006
- Last Updated 07/10/2007
- Taxonomy Code 207VE0102X
- Entity Type Individual
- NPI Number 1700947256
Products in Payments
- NEXTSTELLIS (Drug) $211,884
- Osphena (Drug) $135,468
- INTRAROSA (Drug) $115,596
- Orilissa (Drug) $78,986
- Lupron (Drug) $72,661
- MYFEMBREE (Drug) $55,085
- ESTROGEL (Drug) $52,719
- Veozah (Drug) $37,967
- ANNOVERA (Drug) $31,587
- Essure (Device) $31,032
- ADDYI (Drug) $30,237
- BIJUVA (Drug) $30,027
- MAKENA (Drug) $25,522
- IMVEXXY (Drug) $25,455
- BREMELANOTIDE (Drug) $12,777
- Vagifem (Biological) $9,100
- Mona Lisa Touch (Device) $8,145
- PRALUENT (Drug) $8,080
- Non-Covered $7,521
- Saxenda (Drug) $5,522
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Reproductive Endocrinology Doctors in Washington
Kathleen Devine, M.d, M.D
Reproductive Endocrinology — Payments: $10,955
Reproductive Endocrinology $10,955
Dr. John Csokmay, M.d, M.D
Reproductive Endocrinology — Payments: $717.12
Reproductive Endocrinology $717.12
Kimberly Moon, Md, MD
Reproductive Endocrinology — Payments: $529.92
Reproductive Endocrinology $529.92
Xiaohong Liu
Reproductive Endocrinology — Payments: $450.09
Reproductive Endocrinology $450.09
Jessica Selter, Md, MD
Reproductive Endocrinology — Payments: $419.52
Reproductive Endocrinology $419.52
Francisco Irianni, Md, MD
Reproductive Endocrinology
Reproductive Endocrinology